Targets › NKG2D
6 programs from 6 companies in 7 trials: 7 Phase 1; Oncology; next expected readout Dec 2026.
Functions as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. (UniProt, P26718)
Open in Phaseline: the race on NKG2D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CytoMed Therapeutics Pte | Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2 NKG2DL-targeting CAR-T cell therapy using allogeneic gamma-delta T cells | NKG2D | Phase 1 | Cancer | Dec 2026 |
| Peking University | KD-496 Dual CAR-T cell therapy targeting NKG2D ligands and CLDN18.2 | NKG2D, CLDN18 | Phase 1 | Gastric Cancer | Jun 2027 |
| Antonio Pérez Martínez | NKG2D-CAR memory T cell chimeric antigen receptor (CAR) T cell targeting NKG2D ligands | NKG2D | Phase 1 | Advanced Sarcoma | Jan 2028 |
| Instituto de Investigación Hospital Universitario La Paz | Allogeneic CART-NKG2D cells Anti-NKG2D chimeric antigen receptor Natural-killer group 2, member D T cell therapy | NKG2D | Phase 1 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Jun 2030 |
| Celyad Oncology | CYAD-101 Allogeneic NKG2D-based chimeric antigen receptor T-cell therapy | NKG2D | Phase 1 | Unresectable Metastatic Colorectal Cancer | Feb 2036 |
| Henan Medical University | NKG2D-CAR-NK92 cells NKG2D-CAR-NK92 cells redirect natural killer cells to recognize NKG2D ligands on tumor cel | NKG2D | Phase 1 | Relapsed/Refractory Solid Tumors | – |
Unresectable Metastatic Colorectal Cancer (2) Gastric Cancer (1) Advanced Sarcoma (1) Relapsed/Refractory Solid Tumors (1) Cancer (1) Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
other (3), protein or peptide (1), small molecule (1)
Peking University (1) Antonio Pérez Martínez (1) Henan Medical University (1) CytoMed Therapeutics Pte (1) Celyad Oncology (1) Instituto de Investigación Hospital Universitario La Paz (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.